Pharmaceutical and Biologics Litigation
Overview
Crowell & Moring is home to a team of patent litigators representing and advising clients in cases arising under the “Hatch-Waxman Act” and the Biologics Price Competition and Innovation Act (BPCIA). Our life sciences patent litigation group currently consists of more than 10 intellectual property litigators who bring experience, dedication, and skill to life sciences patent litigation.
Contacts
Insights
Client Alert | 3 min read | 05.21.26
Judge Jennifer Choe-Groves Takes Over Several DNJ Hatch-Waxman Cases
The U.S. Court of International Trade (CIT) is having a big year. While the U.S. Supreme Court’s affirmance of the CIT tariff ruling may be at the top of the headlines, the CIT is also making its mark on Hatch-Waxman pharmaceutical litigation. In late April 2026, the U.S. District Court for the District of New Jersey (DNJ) reassigned numerous Hatch-Waxman patent infringement cases involving 10 different drugs to Judge Jennifer Choe-Groves of the CIT, sitting by designation in the District of New Jersey. The cases currently assigned to Judge Choe-Groves relate to several different drug products, including LYNPARZA® (olaparib), RADICAVA ORS® (edaravone), NEXLETOL®/NEXLIZET® (bempedoic acid), ZEJULA® (niraparib), QULIPTA® (atogepant), UBRELVY® (ubrogepant), CREXONT® (carbidopa and levodopa), EVRYSDI® (risdiplam), SUFLAVE® (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution), and CAPLYTA® (lumateperone).
Client Alert | 3 min read | 05.18.26
“To IPR or Not to IPR?” — Director Squires Offers Clarity, With Data and History
Webinar | 09.19.24
Firm News | 5 min read | 06.06.24
Insights
Patent Cases – An Open Door for MOT Patent Litigation
|01.12.22
Crowell & Moring's Litigation Forecast 2022
- |
09.18.15
Bloomberg BNA Pharmaceutical Law & Industry Report
Professionals
Insights
Client Alert | 3 min read | 05.21.26
Judge Jennifer Choe-Groves Takes Over Several DNJ Hatch-Waxman Cases
The U.S. Court of International Trade (CIT) is having a big year. While the U.S. Supreme Court’s affirmance of the CIT tariff ruling may be at the top of the headlines, the CIT is also making its mark on Hatch-Waxman pharmaceutical litigation. In late April 2026, the U.S. District Court for the District of New Jersey (DNJ) reassigned numerous Hatch-Waxman patent infringement cases involving 10 different drugs to Judge Jennifer Choe-Groves of the CIT, sitting by designation in the District of New Jersey. The cases currently assigned to Judge Choe-Groves relate to several different drug products, including LYNPARZA® (olaparib), RADICAVA ORS® (edaravone), NEXLETOL®/NEXLIZET® (bempedoic acid), ZEJULA® (niraparib), QULIPTA® (atogepant), UBRELVY® (ubrogepant), CREXONT® (carbidopa and levodopa), EVRYSDI® (risdiplam), SUFLAVE® (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution), and CAPLYTA® (lumateperone).
Client Alert | 3 min read | 05.18.26
“To IPR or Not to IPR?” — Director Squires Offers Clarity, With Data and History
Webinar | 09.19.24
Firm News | 5 min read | 06.06.24














